L-ORNITHINE L- ASPARTATE( LOLA) VERSUS STANDARD MEDICAL THERAPY (SMT) FOR IMPROVEMENT OF SARCOPENIA IN PATIENTS WITH CIRRHOSIS - A RANDOMIZED OPEN LABEL TRIAL

被引：0

作者：

Najar, Rameez Raja ^{[1
]}

Sahney, Amrish ^{[1
]}

Wadhavan, Manav ^{[1
]}

Ganesan, Prem Kumar ^{[1
]}

Kumar, Ajay ^{[1
]}

Vij, Jc ^{[1
]}

Berry, Neha ^{[1
]}

Reethesh, S. R. ^{[1
]}

Sondhi, Pulkit ^{[1
]}

Ansari, Md Nuruddin ^{[1
]}

机构：

[1] BLK MAX SS Hosp New Delhi, New Delhi, India

来源：

HEPATOLOGY | 2023年 / 78卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

3055-A

引用

页码：S1373 / S1373

页数：1

共 30 条

[11] ORAL L-ORNITHINE-L-ASPARTATE (LOLA) FOR PATIENTS WITH OVERT HEPATIC ENCEPHALOPATHY TREATED WITH LACTULOSE; A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL
Nimanong, S.
Siwaporn, C.
Sansak, I.
Tanwandee, T.
Charatcharoenwitthaya, P.
Chotiyaputta, W.
Boonyapisit, K.
Pausawasdi, N.
Prachayakul, W.
Pongprasobchai, S.
Leelakusolvong, S.
Manatsathit, S.
Kachintorn, U.
JOURNAL OF HEPATOLOGY, 2010, 52 : S78 - S78
[12] A randomized, double-blind, clinical trial comparing lactulose, l-ornithine l-aspartate, or rifaximin, versus placebo, as primary prophylaxis of hepatic encephalopathy in cirrhotic patients with variceal bleeding
de La Tijera, F. H.
Servin-Caamano, A. I.
Abdo-Francis, J. M.
Salas-Gordillo, F.
Perez-Hernandez, J. L.
Camacho-Aguilera, J.
Alla, S. N.
Jimenez-Ponce, F.
JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S49 - S49
[13] COMPARISON OF STANDARD MEDICAL THERAPY PLUS N ACETYL CYSTEINE (NAC) VERSUS STANDARD MEDICAL THERAPY (SMT) ALONE IN ACUTE ON CHRONIC LIVER FAILURE (DEFINED BY APASL CRITERIA): AN OPEN LABEL RANDOMIZED CONTROLLED TRIAL (PILOT STUDY).
Kumar, Chandan
Panigrahi, Manas Kumar
Padhy, Biswa Mohan
Nayak, Hemanta K.
Samal, Subash Chandra
Bhat, Sunil Jee
HEPATOLOGY, 2021, 74 : 174A - 175A
[14] A PROSPECTIVE RANDOMIZED, OPEN-LABELED PARALLEL GROUP TRIAL OF L- ASPARAGINASE VERSUS PREDNISOLONE IN NEWLY DIAGNOSED PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA PRESENTING WITH HYPERLEUKOCYTOSIS
Gulia, S.
Arora, B.
Narula, G.
Kurkure, P. A.
Chinnaswamy, G.
Prasad, M.
Gujral, S.
Subramaniam, P. G.
PEDIATRIC BLOOD & CANCER, 2013, 60 : 67 - 67
[15] A neoadjuvant, randomized, open-label phase II trial of afatinib (A) versus trastuzumab (T) versus lapatinib (L) in patients (pts) with locally advanced HER2-positive breast cancer (BC).
Rimawi, Mothaffar F.
Aleixo, Sabina B.
Rozas, Ashley Alarcon
Matos Neto, Joao Nunes
Caleffi, Maira
Vinholes, Jeferson J. F.
Figueira, Alicardo Cesar
Souza, Sulene Cunha
Reiriz, Andre B.
Arantes, Heloisa
Uttenreuther-Fischer, Martina Maria
Osborne, C. Kent
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[16] A Single Center, Randomized, Open-Label, Controlled Pilot Study to Demonstrate Efficacy and Safety of the Addition of Inhaled Liposomal Cyclosporine (L-CsA) Therapy versus Standard Therapy Alone in the Treatment of Bronchiolitis Obliterans Syndrome (BOS) Following Lung Transplantation
Iacono, A.
Terrin, M.
Rajakopal, K.
McGrain, J.
Barr, E.
Rinaldi, J.
Patel, A.
Timofte, I.
Kim, J.
Kon, Z.
Sanchez, P. G.
Pierson, R.
Griffith, B.
Pham, S.
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2016, 35 (04): : S44 - S45
[17] Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial
Lieverse, Relinde I. Y.
Van Limbergen, Evert J.
Oberije, Cary J. G.
Troost, Esther G. C.
Hadrup, Sine R.
Dingemans, Anne-Marie C.
Hendriks, Lizza E. L.
Eckert, Franziska
Hiley, Crispin
Dooms, Christophe
Lievens, Yolande
de Jong, Monique C.
Bussink, Johan
Geets, Xavier
Valentini, Vincenzo
Elia, Giuliano
Neri, Dario
Billiet, Charlotte
Abdollahi, Amir
Pasquier, David
Boisselier, Pierre
Yaromina, Ala
De Ruysscher, Dirk
Dubois, Ludwig J.
Lambin, Philippe
BMC CANCER, 2020, 20 (01)
[18] Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial
Relinde I. Y. Lieverse
Evert J. Van Limbergen
Cary J. G. Oberije
Esther G. C. Troost
Sine R. Hadrup
Anne-Marie C. Dingemans
Lizza E. L. Hendriks
Franziska Eckert
Crispin Hiley
Christophe Dooms
Yolande Lievens
Monique C. de Jong
Johan Bussink
Xavier Geets
Vincenzo Valentini
Giuliano Elia
Dario Neri
Charlotte Billiet
Amir Abdollahi
David Pasquier
Pierre Boisselier
Ala Yaromina
Dirk De Ruysscher
Ludwig J. Dubois
Philippe Lambin
BMC Cancer, 20
[19] Patient-reported outcomes with trastuzumab monotherapy versus trastuzumab plus standard chemotherapy as a postoperative adjuvant therapy in HER2-positive elderly breast cancer patients (RESPECT): A randomized, open-label, phase 3 clinical trial
Kobayashi, K.
Taira, N.
Sawaki, M.
Sagawa, N.
Baba, S.
Saito, T.
Kawahara, T.
Hagiwara, Y.
Uemura, Y.
Shimozuma, K.
Ohashi, Y.
Mukai, H.
CANCER RESEARCH, 2019, 79 (04)
[20] Frequency of PD-L1 positivity and microsatellite instability (MSI) in the DANTE trial: Perioperative atezolizumab with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma. A randomized, open-label phase IIb trial of the German gastric group at the AIO and SAKK
Kopp, C.
Lorenzen, S.
Gaiser, T.
Thuss-Patience, P. C.
Schenk, M.
Lindig, U.
Kretzschmar, A.
Heuer, V.
Goekkurt, E.
Haag, G. M.
Knorrenschild, J. Riera
Bolling, C.
Hofheinz, R. D.
Siebenhuener, A. R.
Irahara, N.
Waberer, L.
Pauligk, C.
Gotze, T. O.
Homann, N.
Al-Batran, S-E.
ANNALS OF ONCOLOGY, 2021, 32 : S1069 - S1070

← 1 2 3 →